GW Pharmaceuticals — Investor Presentation (January 2017)
33 slides from GW Pharmaceuticals's investor presentation, Jan 9, 2017
Slide 1: Investor Presentation January 2017
©2017 GW Pharmaceuticals plc | All Rights Reserved Investor Presentation January 2017
Slide 2: GW's Vision
GW’S VISION is to be the global leader in prescription cannabinoid medicines, developing and commercializing pharmaceutical products which address clear unmet needs January 2017 GW Pharmaceuticals plc Investor Presentation 2
Slide 3: Forward-Looking Statements
FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements that are based on our management’s beliefs and assumptions and on information currently available to management . Forward - looking statements include information about our current expectations for future events, in
Slide 4: GW Pharmaceuticals: The World Leader in Cannabinoid Science
GW Pharmaceuticals January 2017 GW Pharmaceuticals plc Investor Presentation 4 • 14 cannabinoids evaluated in pre - clinical research • >80 peer - reviewed publications • Cannabinoids exported to 35 countries for research • 45 Phase 2/3 clinical trials • >55,000 patient - years of human safety data
Slide 5: Epidiolex Treatment-Resistant Epilepsy Overview
Epidiolex ® Treatment - Resistant Epilepsy Overview • Extensive pre - clinical research since 2007 - Cannabidiol (CBD) shows in vivo and in vitro efficacy • Novel mechanism of action in epilepsy - CBD does not act through cannabinoid (CB) receptors or sodium channels - Prime targets are GPR55 and ad
Slide 6: Significant Unmet Need in Epilepsy
• 2.2 million U.S. patients with epilepsy (470,000 children) - ~ One third of patients are pharmacoresistant with seizures persisting despite multiple antiepileptic drugs (AEDs) • Childhood - onset epilepsy - Multiple distinct orphan syndromes, almost none with a specific indicated therapy - Many sy
Slide 7: The Epidiolex Story: IND to NDA in Years
The Epidiolex ® Story: IND to NDA in 3 Years 7 Q4 ‘12 First child treated with Epidiolex Q1 ‘14 EAPs initiated Q4 ‘14 Dravet 1 Part A started Q2 - 4 ‘15 3 Phase 3 studies in DS and LGS started and enrolled Q2 ‘14 FDA grants GW IND Formal GW CBD development program begins Q1 2016 Dravet 1 topline res
Slide 8: Epidiolex Expanded Access Program
• FDA authorized, physician - sponsored expanded access program (EAP) initiated in early 2014 - Children and young adults with multiple etiologies, all with treatment - resistant epilepsy - ~20 physician site EAPs and 6 state sponsored EAP programs - ~1,100 patients approved for treatment by FDA • M
Slide 9: Clinical Programs
Clinical Programs
Slide 10: Epidiolex Phase 3 Program Overview
Epidiolex ® Phase 3 Program Overview 10 > 97% of completers continued into OLEX January 2017 GW Pharmaceuticals plc Investor Presentation Physician Sponsored GW Sponsored Dravet Syndrome Lennox - Gastaut Syndrome Tuberous Sclerosis Complex Infantile Spasms Childhood Epilepsy Syndromes 2015 2016 2017
Slide 11: 1st Phase 3 LGS Study Principal Efficacy Results
1st Phase 3 LGS Study Principal Efficacy Results GW Pharmaceuticals plc Investor Presentation 11 44 49 22 20 0 10 20 30 40 50 60 Treatment Period Maintenance Period Median % Reduction 41 45 14 15 0 5 10 15 20 25 30 35 40 45 50 Treatment Period Maintenance Period Median % Reduction Drop Seizures Tota
Slide 12: 1st Phase 3 Dravet Syndrome Study Principal Efficacy Results
39 41 13 16 0 5 10 15 20 25 30 35 40 45 Treatment Period Maintenance Period Median % Reduction 29 37 9 10 0 5 10 15 20 25 30 35 40 Treatment Period Maintenance Period Median % Reduction 1st Phase 3 Dravet Syndrome Study Principal Efficacy Results GW Pharmaceuticals plc Investor Presentation 12 p=0.0
Slide 13: 2nd Phase 3 LGS Topline Efficacy Results
2nd Phase 3 LGS (Multiple Dose Study) Topline Efficacy Results GW Pharmaceuticals plc Investor Presentation 13 42 37 17 0 5 10 15 20 25 30 35 40 45 Treatment Period Median % Reduction 20mg/kg/day CBD (n=76) 10mg/kg/day CBD (n=73) Placebo (n=76) p=0.0047 p=0.0016 Drop Seizures January 2017 Source: GW
Slide 14: Phase 3 Global Impression of Change
Phase 3 Global Impression of Change GW Pharmaceuticals plc Investor Presentation 14 January 2017 17.9 16.7 23.8 32.1 8.3 1.2 0 5.9 10.6 17.6 50.6 10.6 2.4 2.4 0 10 20 30 40 50 60 Very Much Improved Much Improved Slightly Improved No Change Slightly Worse Much Worse Very Much Worse Percentage of Pati
Slide 15: Phase 3 Responder Analysis
Phase 3 Responder Analysis GW Pharmaceuticals plc Investor Presentation 15 LGS 1 Dravet syndrome 1 January 2017 Source: American Epilepsy Society 2016 Annual Meeting poster presentations 20 mg/kg/day CBD (n=86) Placebo (n=85) 20 mg/kg/day CBD (n=61) Placebo (n=59)
Slide 16: Phase 3 Safety Profile
Phase 3 Safety Profile • Consistent AE profile across pivotal, EAP and state programs. Most common AEs (>10% of patients) in Phase 3 trials include: - Somnolence, diarrhea, decreased appetite, fatigue, pyrexia, vomiting, lethargy, upper respiratory tract infection, convulsion • SAEs consistent with
Slide 17: Drug-Drug Interactions
• Drug - drug interactions in epilepsy are commonplace and a routine matter for physicians - DDIs indicated on package insert of most commonly used AEDs such as clobazam , valproate, lamotrigine, stiripentol and topiramate - Generally handled through dose adjustment of concomitant AEDs • Agreement w
Slide 18: Comprehensive NDA Submission Package
Comprehensive NDA Submission Package • Extensive FDA interactions throughout EAP and Phase 3 program - Clinical and pre - clinical pre - NDA meeting held in July 2016 - Proposed pre - clinical and clinical content of the NDA submission was confirmed - CMC pre - NDA meeting held in November 2016 - Pr
Slide 19: Additional Epidiolex Orphan Indications: TSC and Infantile Spasms
• Selection of these indications driven by encouraging EAP data • Tuberous Sclerosis Complex (~25,000 U.S. patients) - Single Phase 3 pivotal trial commenced - TSC is a genetic disorder that results from a mutation in tumor suppression genes TSC1 or TSC2 and causes non - malignant tumors to form in
Slide 20: Tuberous Sclerosis Complex – Recent Clinical Data
• 18 patients from Epidiolex Expanded Access Program with TSC • 48.8% median percent change in weekly seizure frequency after 3 months of treatment • 50% responder rate after 3 months of treatment • After 3 months, median seizure frequency decreased or all seizure types experienced in study patients
Slide 21: Commercialization
Commercialization
Slide 22: Commercial Manufacturing
Commercial Manufacturing 22 Growing & Harvesting Drying & Processing Crystallisation (API) Drug Product Manufacture Bottling & Labeling GMP Non - GMP • GW has operated under commercial GMP licenses issued outside the U.S. since 2005 • Manufacturing scalable through in - house and 3 rd party faciliti
Slide 23: Epidiolex Commercial Exclusivity
• Orphan Designation - 7 years plus expected 6 - month pediatric extension - 10 years in the EU • Intellectual Property - Current portfolio includes 12 distinct patent families either granted or filed in the treatment of epilepsy and formulations - The latest expiry date of these families runs to Ju
Slide 24: Epidiolex Rescheduling
• FDA approval necessitates that Epidiolex be moved out of Schedule I once it has an “accepted medical use” • At the time of NDA approval, FDA recommend the appropriate lower schedule (II - V) based on the abuse liability data submitted as part of the NDA • Following NDA approval, DEA has up to 90 d
Slide 25: Epidiolex Commercialization Status
• Global commercialization rights to Epidiolex fully - owned by GW Pharmaceuticals Group companies • U.S . Launch Preparations - Senior commercial organization in place, many of whom have deep previous epilepsy experience - Expected sales force of approximately 50 - 60 sales professionals targeting
Slide 26: Additional Programs
Additional Programs
Slide 27: GW's Cannabinoid Platform: A Proprietary Growth Engine Beyond Epidiolex
• Cannabis plant is a unique source of >100 cannabinoid molecules capable of targeting diseases across therapeutic areas and mechanisms - TRP channels, adenosine uptake, serotonin receptors, endocannabinoid system • GW has a deep pipeline of additional cannabinoid product candidates • Focus on orpha
Slide 28: CBDV Program
• CBDV has shown anti - epileptic properties across a range of in vitro and in vivo animal models of epilepsy and different from CBD - CBDV looks to be differentiated from CBD in four key ways: efficacy profile in seizure models, metabolic profile, pharmacological profile and has different physico -
Slide 29: NHIE Program – Intravenous CBD
NHIE Program – Intravenous CBD • NHIE: Acute or sub - acute brain injury due to asphyxia resulting from deprivation of oxygen during birth • GW has shown neuroprotective effects of CBD in three nonclinical models of NHIE across three species • Orphan Designation and Fast Track granted for CBD in NHI
Slide 30: Recurrent Glioblastoma Multiforme (GBM) Program
• THC:CBD product candidate for the treatment of GBM • GBM is the most common and most aggressive type of malignant primary brain tumor 1,2 - Typically patients succumb to the disease approximately 15 months after diagnosis - Treatment for GBM remains challenging and no long - term treatments are cu
Slide 31: Key Financial Data
Key Financial Data January 2017 GW Pharmaceuticals plc Investor Presentation 31 Clean up ICON Cash at 30 September 2016 $483m 2017 cash outflow guidance ($ 30m Capex, $ 100m – $120m Opex ) $130m – $150m Share Capital Current Options Fully Diluted ADS/m 25.3 0.9 26.2
Slide 32: Upcoming Milestones/Newsflow
Upcoming Milestones/ Newsflow GW Pharmaceuticals plc Investor Presentation 32 January 2017 Expected Timing EPIDIOLEX REGULATORY NDA submission with FDA End H1 2017 EMA submission H2 2017 EPIDIOLEX DATA Dravet Phase 3 data publication Q1 2017 2nd LGS Trial data presentation Q2 2017 Infantile spasms t
Slide 33: Thank You
Thank You GW Pharmaceuticals plc NASDAQ: GWPH Stephen Schultz, VP Investor Relations sschultz@gwpharm.com + 1 401 - 500 - 6570 SS10
GW Pharmaceuticals — Investor Presentation (January 2017) on 6ix